- Home
- WAVE vs APLM Comparison
WAVE vs APLM Comparison
Compare WAVE & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAVE
- APLM
- Stock Information
- Founded
- WAVE 2011
- APLM 2016
- Country
- WAVE Israel
- APLM United States
- Employees
- WAVE N/A
- APLM N/A
- Industry
- WAVE Electric Utilities: Central
- APLM Blank Checks
- Sector
- WAVE Utilities
- APLM Finance
- Exchange
- WAVE Nasdaq
- APLM Nasdaq
- Market Cap
- WAVE 43.2M
- APLM 12.3M
- IPO Year
- WAVE 2021
- APLM N/A
- Fundamental
- Price
- WAVE $8.35
- APLM $8.50
- Analyst Decision
- WAVE Strong Buy
- APLM Strong Buy
- Analyst Count
- WAVE 1
- APLM 2
- Target Price
- WAVE $15.00
- APLM $425.00
- AVG Volume (30 Days)
- WAVE 24.3K
- APLM 5.0K
- Earning Date
- WAVE 03-03-2025
- APLM 03-25-2025
- Dividend Yield
- WAVE N/A
- APLM N/A
- EPS Growth
- WAVE N/A
- APLM N/A
- EPS
- WAVE N/A
- APLM N/A
- Revenue
- WAVE $168,000.00
- APLM $2,101,000.00
- Revenue This Year
- WAVE $325.00
- APLM N/A
- Revenue Next Year
- WAVE $361.48
- APLM N/A
- P/E Ratio
- WAVE N/A
- APLM N/A
- Revenue Growth
- WAVE N/A
- APLM 70.54
- 52 Week Low
- WAVE $1.01
- APLM $6.20
- 52 Week High
- WAVE $17.63
- APLM $75.00
- Technical
- Relative Strength Index (RSI)
- WAVE 51.75
- APLM 55.81
- Support Level
- WAVE $6.70
- APLM $6.36
- Resistance Level
- WAVE $7.85
- APLM $6.70
- Average True Range (ATR)
- WAVE 0.79
- APLM 0.49
- MACD
- WAVE 0.03
- APLM 0.20
- Stochastic Oscillator
- WAVE 63.16
- APLM 72.50
About WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.